SCHEMBL5876033

SCHEMBL5876033

Cc1ccc(S(=O)(=O)n2nc(NC3CCC3)c3c2CC(c2ccccc2)C=C3)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
USP2 O75604 1/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NOD2 Q9HC29 1/20 0.35
NOD1 Q9Y239 1/20 0.35
ACHE P22303 1/20 0.35
SLC9A1 P19634 1/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
LMNA P02545 2/20 0.33
HTR6 P50406 1/20 0.33
FPR1 P21462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876462 0.96 MMP2 (0.39) MMP2NPSR1NR1H2NR1H3USP2
SCHEMBL5876671 0.85 NPSR1 (0.40) MMP2NPSR1NR1H2NR1H3SMN1; SMN2
SCHEMBL5876072 0.81 NPSR1 (0.43) MMP2NPSR1NR1H2NR1H3SMN1; SMN2
SCHEMBL5876526 0.79 NPSR1 (0.44) MMP2NPSR1NR1H2NR1H3USP2
SCHEMBL5876198 0.79 USP2 (0.37) MMP2NPSR1NR1H2NR1H3USP2
SCHEMBL5876490 0.78 USP2 (0.36) MMP2NPSR1NR1H2NR1H3USP2
SCHEMBL5877353 0.75 NOD2 (0.36) NPSR1NR1H2NR1H3USP2MAPK1
SCHEMBL5876674 0.75 USP2 (0.35) NR1H2NR1H3USP2MAPK1NOD2
SCHEMBL5876201 0.74 USP2 (0.34) NR1H2NR1H3USP2MAPK1SMN1; SMN2
SCHEMBL6649960 0.74 MAPT (0.33) NPSR1SMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed
EP-1414805-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY Aventis Pharma S.A. (FR) 2004-05-06 EP disclosed
WO-2003011833-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY AVENTIS PHARMA S.A. (FR) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT MMP2 3720/4885NPSR1 797/4885NR1H2 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.